Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 385

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 8
Chunk 385
---
provide her with the qualifications and skills to serve as a director.

85

Dr. William Forbes, Director

Dr. William Forbes joined our
Board of Directors in August 2018 and serves on our nominating committee. He brings to our Board of Directors more than 30 years of pharmaceutical
product development experience and, working with health authorities in the U.S. and Europe, has contributed to numerous marketing approvals
spanning a diverse range of therapeutic areas. Dr. Forbes has served as the Chief Development Officer of Trevi Therapeutics, a clinical-stage
pharmaceutical company focused on serious neurologically mediated diseases since February 2021. Prior to joining Trevi, Dr. Forbes was
at Salix Pharmaceuticals as the Chief Development Officer and also Head of Medical and R&D from February 2015 to June 2015. Prior
to Salix, Dr. Forbes spent 15 years in Clinical Development & Regulatory Affairs and Clinical Research at a number of global pharmaceutical
companies.

Our Board of Directors believes
that Dr. Forbes’ experience and perspective advising the Company, as well as his depth of operating and senior management experience
in our industry, provide him with the qualifications and skills to serve as a director.

Robert F. Carey, Director

Robert Carey joined our Board
of Directors in February 2019 and serves on our audit committee. He has an extensive track record of accomplishment within the biopharmaceutical
and healthcare investment banking industry. He has assisted biotech and specialty pharma companies raise more than $10 billion in initial
public offerings, follow-on offerings, debt offerings, and private placements. He has served as a financial advisor on mergers, acquisitions,
and strategic alliance transactions with a total deal value of more than $10 billion. From July 2020 until December 2023, Mr. Carey was
co-founder and President of ACELYRIN, INC., a biopharmaceutical company developing life-changing drug therapies. Mr. Carey previously
served as Executive Vice President and Chief Business Officer at Horizon Therapeutics plc from March 2014 to September 2019, during which
Horizon Therapeutics deployed in excess of $3.5 billion to acquire or license eight commercial products and three products in development
and grew net sales from $74 million in 2013 to approximately $1.2 billion in 2018, a compound annual growth rate of 75%. Before Horizon,
he spent more than 11 years as Managing Director and Head of the Life Sciences Investment Banking